ReviewFrontiers in psychiatry2018
Constructing the Immune Signature of Schizophrenia for Clinical Use and Research; An Integrative Review Translating Descriptives Into Diagnostics.
Review in Frontiers in psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- The role of glial cells in mental illness: a systematic review on astroglia and microglia as potential players in schizophrenia and its cognitive and emotional aspects.Frontiers in cellular neuroscience · 2024Pooled it
- Mortality from coronavirus disease 2019 (Covid-19) in patients with schizophrenia: A systematic review, meta-analysis and meta-regression.General hospital psychiatryPooled it
- The Role of Total White Blood Cell Count in Antipsychotic Treatment for Patients with Schizophrenia.Current neuropharmacology · 2024Trial
- Impact of atypical antipsychotics on cytokine profiles in schizophrenia: An 8-week longitudinal study.Indian journal of pharmacology · 2026Article
- The NLRP3 inflammasome: pathophysiology and therapeutic implications for schizophrenia and neuropsychiatric disorders.Molecular psychiatry · 2026Review
- Modeling the Role of Baseline Risk and Additional Study-Level Covariates in Meta-Analysis of Treatment Effects.Statistics in medicine · 2025Article
- Prednisolone add-on in early phase schizophrenia: A randomized, double-blind, placebo-controlled pilot study.Brain, behavior, & immunity - health · 2025Article
- Minor immunomodulatory effects of psychotropics suggested in severe mental disorders: Associations of antipsychotics with beta defensin 2, antidepressants with C-reactive protein, and mood stabilizers with soluble interleukin 2 receptor.European psychiatry : the journal of the Association of European Psychiatrists · 2025Article
- Intrinsic metabolic and immune impairments in a genetic mouse model of schizophrenia.Schizophrenia (Heidelberg, Germany) · 2025Article
- Effects of positive mGlu5 modulation on DJournal of psychopharmacology (Oxford, England) · 2025Article
- Sex differences in the peripheral levels of cytokines during 12-month antipsychotic treatment in a drug-naïve schizophrenia spectrum cohort.Brain, behavior, & immunity - health · 2025Article
- Limited evidence of association between dysregulated immune marker levels and telomere length in severe mental disorders.Acta neuropsychiatrica · 2025Article
- Shared Genetic Loci Between Schizophrenia and White Blood Cell Counts Suggest Genetically Determined Systemic Immune Abnormalities.Schizophrenia bulletin · 2023Article
- Altered neutrophil-to-lymphocyte ratio in patients with non-affective first episode psychosis and its relationship with symptom severity and cognitive impairment.Scientific reports · 2023Article
- The Role of Dopamine D3 Receptors, Dysbindin, and Their Functional Interaction in the Expression of Key Genes for Neuroplasticity and Neuroinflammation in the Mouse Brain.International journal of molecular sciences · 2023Article
- A Novel Localization of METTL7A in Bergmann Glial Cells in Human Cerebellum.International journal of molecular sciences · 2023Article
- Alterations in inflammatory markers after a 12-week exercise program in individuals with schizophrenia-a randomized controlled trial.Frontiers in psychiatry · 2023Article
- Analysis of networks in the dorsolateral prefrontal cortex in chronic schizophrenia: Relevance of altered immune response.Frontiers in pharmacology · 2023Article
- Evidence for increased DNA damage repair in the postmortem brain of the high stress-response group of schizophrenia.Frontiers in psychiatry · 2023Article
- Microglia sequelae: brain signature of innate immunity in schizophrenia.Translational psychiatry · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is considered a syndrome comprised by several disease phenotypes, covering a range of underlying pathologies. One of these disease mechanisms seems to involve immune dysregulation and neuroinflammation. While the current dopamine receptor-blocking antipsychotic drugs decrease psychotic symptoms and prevent relapse in the majority of patients with schizophrenia, there is a huge need to explore new treatment options that target other pathophysiological pathways. Such studies should aim at identifying robust biomarkers in order to diagnose and monitor the immune biophenotype in schizophrenia and develop better selection procedures for clinical trials with anti-inflammatory and immune-modulating drugs. In this focused review, we describe available methods to assess inflammatory status and immune disturbances
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.